Treating recurrent HNSCC with radiation and dual TGF-Beta/PD-L1.

使用放射和双重 TGF-Beta/PD-L1 治疗复发性 HNSCC。

基本信息

  • 批准号:
    10477461
  • 负责人:
  • 金额:
    $ 32.81万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-01 至 2026-08-31
  • 项目状态:
    未结题

项目摘要

SUMMARY, Project 2 Radiation therapy (RT) is commonly used for locally recurrent head and neck squamous cell carcinoma (HNSCCs), yet no standard concomitant systemic therapy exists, and RT resistance rates are high. Antibodies against programmed death-1 (PD-1) are FDA approved for treating relapsed/recurrent HNSCCs, but the response rate is low. RT induces anti-tumor immunity by causing DNA damage and tumor cell killing that release neoantigens to trigger an “in situ tumor vaccine” and activation of STING (stimulator of IFN genes) for local and systemic immune activation. Conversely, RT also induces transforming growth factor-β1 (TGFβ1), an immune suppressor, and PD-L1, a ligand of PD-1. These RT effects make dual TGFβ/PD-L1 inhibition a rational combination being tested in this project. We have reported that TGFβ1 is elevated in >60% of tobacco-associated HNSCCs. TGFβ1-mediated DNA repair contributes to RT resistance. TGFβ1 also contributes to RT-induced toxicity, e.g., oral mucositis and fibrosis. Using our mouse HNSCC models, we found that TGFβ/PD-L1 dual inhibition eradicated SCCs better than anti-PD-L1 alone in tumors with high TGFβ1 levels and high numbers of PD-L1+/CD11b+ cells. We also found that TGFβ inhibition reduced metastases in athymic mice correlated with reduced CD11b+ myeloid cells. We hypothesize that in advanced HNSCCs, TGFβ/PD-L1 dual inhibition enhances RT-induced in situ vaccination, reverses immune suppression, and overcome RT resistance via T cell-dependent and -independent mechanisms. We will test this hypothesis with experimental therapeutics, mechanistic studies and analyses of HNSCC patient specimens. Aim 1 will determine if TGFβ/PD- L1 dual inhibition enhances RT-induced in situ vaccination and systemic immune activation in oral SCC mouse models. Experimental therapeutics of RT plus TGFβ/PD-L1 dual inhibition will be performed using mouse SCC lines transplanted orthotopically to syngeneic mice, and T-cell dependent anti-tumor mechanisms will be analyzed at the cellular and molecular levels. Aim 2 will determine how RT regimens in combination with TGFβ/PD-L1 inhibition target tumor epithelial death and myeloid cells in mouse and human HNSCC models. T cell-independent therapeutic benefit of RT in combination with TGFβ/PD-L1 inhibition will be analyzed. Aim 3 will conduct a Phase Ib trial for RT with M7824 (TGFβ/PD-L1 bidirectional inhibitor) in locally recurrent and oligometastatic HNSCC patients and identify cellular and molecular markers as therapeutic targets. By performing the proposed studies, we aim to bring a therapeutic intervention in real time to simultaneously enhance immunotherapy and reduce RT resistance in HNSCC patients with poor prognosis. Additionally, identifying predictive markers to the proposed treatment will lead to a true biomarker-driven Phase II trial with pre-selected patients.
项目二总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Xiao-Jing Wang其他文献

Xiao-Jing Wang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Xiao-Jing Wang', 18)}}的其他基金

BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
  • 批准号:
    10796340
  • 财政年份:
    2022
  • 资助金额:
    $ 32.81万
  • 项目类别:
BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
  • 批准号:
    10594019
  • 财政年份:
    2022
  • 资助金额:
    $ 32.81万
  • 项目类别:
BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
  • 批准号:
    10481521
  • 财政年份:
    2022
  • 资助金额:
    $ 32.81万
  • 项目类别:
Treating recurrent HNSCC with radiation and dual TGF-Beta/PD-L1.
使用放射和双重 TGF-Beta/PD-L1 治疗复发性 HNSCC。
  • 批准号:
    10704598
  • 财政年份:
    2021
  • 资助金额:
    $ 32.81万
  • 项目类别:
Treating recurrent HNSCC with radiation and dual TGF-Beta/PD-L1.
使用放射和双重 TGF-Beta/PD-L1 治疗复发性 HNSCC。
  • 批准号:
    10268846
  • 财政年份:
    2021
  • 资助金额:
    $ 32.81万
  • 项目类别:
Proprietary drug to treat radiodermatitis
治疗放射性皮炎的专利药物
  • 批准号:
    10269035
  • 财政年份:
    2020
  • 资助金额:
    $ 32.81万
  • 项目类别:
Mechanisms of Breaking Indolence in Squamous Cell Carcinoma
打破鳞状细胞癌惰性的机制
  • 批准号:
    9137250
  • 财政年份:
    2016
  • 资助金额:
    $ 32.81万
  • 项目类别:
Mechanisms and Therapeutic Targets of SCC Metastasis
SCC转移的机制和治疗靶点
  • 批准号:
    10731726
  • 财政年份:
    2016
  • 资助金额:
    $ 32.81万
  • 项目类别:
Mechanisms and Therapeutic Targets of SCC Metastasis
SCC转移的机制和治疗靶点
  • 批准号:
    10356069
  • 财政年份:
    2016
  • 资助金额:
    $ 32.81万
  • 项目类别:
Testing Smad7-based biologics for treating chronic wounds
测试基于 Smad7 的生物制剂治疗慢性伤口
  • 批准号:
    8779367
  • 财政年份:
    2014
  • 资助金额:
    $ 32.81万
  • 项目类别:

相似海外基金

Life outside institutions: histories of mental health aftercare 1900 - 1960
机构外的生活:1900 - 1960 年心理健康善后护理的历史
  • 批准号:
    DP240100640
  • 财政年份:
    2024
  • 资助金额:
    $ 32.81万
  • 项目类别:
    Discovery Projects
Development of a program to promote psychological independence support in the aftercare of children's homes
制定一项计划,促进儿童之家善后护理中的心理独立支持
  • 批准号:
    23K01889
  • 财政年份:
    2023
  • 资助金额:
    $ 32.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
  • 批准号:
    10452217
  • 财政年份:
    2022
  • 资助金额:
    $ 32.81万
  • 项目类别:
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
  • 批准号:
    10670838
  • 财政年份:
    2022
  • 资助金额:
    $ 32.81万
  • 项目类别:
Aftercare for young people: A sociological study of resource opportunities
年轻人的善后护理:资源机会的社会学研究
  • 批准号:
    DP200100492
  • 财政年份:
    2020
  • 资助金额:
    $ 32.81万
  • 项目类别:
    Discovery Projects
Creating a National Aftercare Strategy for Survivors of Pediatric Cancer
为小儿癌症幸存者制定国家善后护理策略
  • 批准号:
    407264
  • 财政年份:
    2019
  • 资助金额:
    $ 32.81万
  • 项目类别:
    Operating Grants
Aftercare of green infrastructure: creating algorithm for resolving human-bird conflicts
绿色基础设施的善后工作:创建解决人鸟冲突的算法
  • 批准号:
    18K18240
  • 财政年份:
    2018
  • 资助金额:
    $ 32.81万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of an aftercare model for children who have experienced invasive procedures
为经历过侵入性手术的儿童开发善后护理模型
  • 批准号:
    17K12379
  • 财政年份:
    2017
  • 资助金额:
    $ 32.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a Comprehensive Aftercare Program for children's self-reliance support facility
为儿童自力更生支持设施制定综合善后护理计划
  • 批准号:
    17K13937
  • 财政年份:
    2017
  • 资助金额:
    $ 32.81万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Project#2 Extending Treatment Effects Through an Adaptive Aftercare Intervention
项目
  • 批准号:
    8742767
  • 财政年份:
    2014
  • 资助金额:
    $ 32.81万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了